Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inovatyon second-line chemotherapy ovarian cancer
ISRCTN55984729Phase 3Completed
- Sponsor
- Mango
- Start
- May 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Yondelis + pegylated liposomal doxorubicin with Carboplatin + pegylated liposomal doxorubicin (2 arms). Started May 2011; status: completed.
02
Drugs
trabectedindoxorubicincarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ISRCTN55984729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN55984729.